ART-123

DRUG5 trials

Sponsors

Artisan Pharma, Inc., Asahi Kasei Pharma America Corporation, Asahi Kasei Pharma Corporation

Conditions

CoagulopathyDisseminated Intravascular CoagulationIdiopathic Pulmonary FibrosisSepsisSepsis and CoagulopathySevere Sepsis

Phase 2

Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation

CompletedNCT00487656

Artisan Pharma, Inc.Disseminated Intravascular Coagulation, Sepsis

Start: 2007-07-31End: 2010-08-31Updated: 2011-05-18

Phase 3

Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy

CompletedNCT01598831

Asahi Kasei Pharma America CorporationCoagulopathy, Severe Sepsis

Start: 2012-10-29End: 2019-02-28Updated: 2020-04-21

Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

CompletedNCT02739165

Asahi Kasei Pharma CorporationIdiopathic Pulmonary Fibrosis

Start: 2016-05-31End: 2018-12-31Updated: 2019-01-18

The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy

WithdrawnNCT03517501

Asahi Kasei Pharma America CorporationSepsis and Coagulopathy

Start: 2019-07-31End: 2023-05-31Updated: 2019-09-13

Phase 4

Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal Impairment

CompletedNCT01704001

Asahi Kasei Pharma CorporationDisseminated Intravascular Coagulation

Start: 2012-10-31End: 2014-06-30Target: 40Updated: 2017-02-15

Related Papers

Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy

Critical Care Medicine2020-06-1262 citations

Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial

American Journal of Respiratory and Critical Care Medicine2020-01-0976 citations

Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy

JAMA2019-05-19348 citations

Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial

BMJ Open2016-12-0146 citations